Fluvoxamine May Prevent Clinical Deterioration in Mild COVID-19
An early trial of fluvoxamine to treat mild coronavirus disease 2019 (COVID-19) showed promising results, suggesting the antidepressant may help ward off clinical deterioration in patients with mild symptoms.